Search Results - "Foltz, Lynda M."

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis by Mascarenhas, John O, Talpaz, Moshe, Gupta, Vikas, Foltz, Lynda M, Savona, Michael R, Paquette, Ronald, Turner, A Robert, Coughlin, Paul, Winton, Elliott, Burn, Timothy C, O'Neill, Peter, Clark, Jason, Hunter, Deborah, Assad, Albert, Hoffman, Ronald, Verstovsek, Srdan

“…Combined Janus kinase 1 (JAK1) and JAK2 inhibition therapy effectively reduces splenomegaly and symptom burden related to myelofibrosis but is associated with…”
Get full text

Hodgkin's Lymphoma in Adolescents by FOLTZ, Lynda M, SONG, Kevin W, CONNORS, Joseph M

“…To compare the clinical presentation, response to treatment, and long-term outcome of Hodgkin's lymphoma (HL) presenting in adolescents and young adults. The…”
Get full text

Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era by Ambler, Kimberley L. S., Vickars, Linda M., Leger, Chantal S., Foltz, Lynda M., Montaner, Julio S. G., Harris, Marianne, Lima, Viviane Dias, Leitch, Heather A.

“…The characteristics of HIV-associated ITP were documented prior to the HAART era, and the optimal treatment beyond HAART is unknown. We performed a review of…”
Get full text

VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation by Cherniawsky, Hannah, Friedmann, Jordan, Nicolson, Hamish, Dehghan, Natasha, Stubbins, Ryan J., Foltz, Lynda M., Leitch, Heather A., Sreenivasan, Gayatri M., Ambler, Kimberley L. S., Nevill, Thomas J., McGinnis, Eric, Wilson, Lorena, Beck, David B., Chen, Luke Y. C., Marcon, Krista M.

“…Myeloid and erythroid precursor vacuolation is a common dysplastic finding associated with myeloid malignancies, toxins, drug, and nutritional deficiencies. It…”
Get full text

Recognition and management of methemoglobinemia and hemolysis in a G6PD‐deficient patient on experimental anticancer drug Triapine by Foltz, Lynda M., Dalal, Bakul I., Wadsworth, Louis D., Broady, Raewyn, Chi, Kim, Eisenhauer, Elizabeth, Kobayashi, Ken, Kollmannsburger, Christian

“…We report occurrence of severe methemoglobinemia in a patient on novel experimental anti‐cancer drug, Triapine. Treatment with methylene blue led to massive…”
Get full text

Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis by Leitch, Heather A, Chan, Christopher, Leger, Chantal S, Foltz, Lynda M, Ramadan, Khaled M, Vickars, Linda M

“…Abstract Retrospective analyses suggest iron overload is associated with inferior survival (OS) in lower risk MDS and iron chelation therapy (ICT) with…”
Get full text

Published guidelines versus real‐life practice in the diagnosis and treatment of essential thrombocythemia by Peterson, Erica A., Zypchen, Leslie, Lee, Vivian H. Y., Nitta, Janet, Foltz, Lynda M.

Get full text

Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy by Leitch, Heather A., Chase, Jocelyn M., Goodman, Trisha A., Ezzat, Hatoon, Rollins, Meaghan D., Wong, Dominic H.C., Badawi, Maha, Leger, Chantal S., Ramadan, Khaled M., Barnett, Michael J., Foltz, Lynda M., Vickars, Linda M.

“…Many patients with primary myelofibrosis (PMF) become red blood cell (RBC) transfusion dependent (TD), risking iron overload (IOL). Iron chelation therapy…”
Get full text

Barriers To Diagnosis In Myeloproliferative Neoplasms by Yip, Raymond H L, Foltz, Lynda M

“…Timely diagnosis of patients (pts) with polycythemia vera (PV) and essential thrombocythemia (ET) is important given the risks of thrombotic and hemorrhagic…”
Get full text

Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1 by Mesa, Ruben A., Hudgens, Stacie, Floden, Lysbeth, Palmer, Jeanne, Gupta, Vikas, Mclornan, Donal P., McMullin, Mary Frances, Kiladjian, Jean-Jacques, Foltz, Lynda M., Platzbecker, Uwe, Fox, Maria Laura, Mead, Adam J., Ross, David M., Oh, Stephen T., Perkins, Andrew, Leahy, Michael F., Deheshi, Samineh, Donahue, Rafe, Klencke, Barbara J., Verstovsek, Srdan

“…Abstract only e19040 Background: Clinical trials investigating JAK1/JAK2 inhibitors for myelofibrosis (MF) subjects have measured symptom improvement as a…”
Get full text

Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF) by Al-Ali, Haifa Kathrin, Stalbovskaya, Viktoriya, Gopalakrishna, Prashanth, Perez Ronco, Julian, Foltz, Lynda M

“…▪ BACKGROUND: Ruxolitinib (RUX) is a potent JAK1/JAK2 inhibitor that has demonstrated rapid and durable reductions in splenomegaly, improvements in MF-related…”
Get full text

PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks by Verstovsek, Srdan, Mesa, Ruben A., Foltz, Lynda M, Gupta, Vikas, Mascarenhas, John O., Ritchie, Ellen K., Hoffman, Ronald, Silver, Richard T., Kremyanskaya, Marina, Pozdnyakova, Olga, Hasserjian, Robert P., Trehu, Elizabeth, Salama, Mohamed E, Kantarjian, Hagop M, Gotlib, Jason

“…Background: PRM-151 (PRM) is a recombinant form of pentraxin-2, an endogenous human protein that acts at sites of tissue damage, inducing macrophage…”
Get full text

Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF) by Griesshammer, Martin, Vannucchi, Alessandro M., le Coutre, Philipp, Tavares, Renato S, Al-Ali, Haifa Kathrin, Raanani, Pia, Gupta, Vikas, Foltz, Lynda M, Giraldo, Pilar, Bouard, Catherine, Perez Ronco, Julian, Ghosh, Jagannath, Martino, Bruno

“…BACKGROUND: Ruxolitinib is a potent JAK1/JAK2 inhibitor that has demonstrated durable reductions in splenomegaly and MF-related symptoms and improved survival…”
Get full text

Safety and Efficacy of Ruxolitinib Retreatment after Treatment Interruption in Patients Enrolled in an Open-Label, Multicenter, Expanded-Access Study in Myelofibrosis by Gupta, Vikas, Tavares, Renato S, Griesshammer, Martin, Foltz, Lynda M, Raanani, Pia, Giraldo, Pilar, Al-Ali, Haifa Kathrin, Martino, Bruno, Tannir, Bayane, Ronco, Julian Perez, Ghosh, Jagannath, Vannucchi, Alessandro M.

“…BACKGROUND: Ruxolitinib is a potent JAK1/JAK2 inhibitor that has demonstrated durable reductions in splenomegaly and myelofibrosis (MF)-related symptoms…”
Get full text

Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results by Verstovsek, Srdan, Mesa, Ruben A., Foltz, Lynda M, Gupta, Vikas, Mascarenhas, John O, Ritchie, Ellen K., Hoffman, Ronald, Silver, Richard T., Kremyanskaya, Marina, Pozdnyakova, Olga, Hasserjian, Robert P, Trehu, Elizabeth, Kantarjian, Hagop M., Gotlib, Jason R.

“…PRM-151 (PRM) is a recombinant form of Pentraxin-2, an endogenous human protein that acts at sites of tissue damage, inducing macrophage differentiation to…”
Get full text

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis by Mascarenhas, John O, Talpaz, Moshe, Gupta, Vikas, Foltz, Lynda M, Savona, Michael R, Paquette, Ron, Turner, Robert, Coughlin, Paul, Winton, Elliott, Hunter, Deborah, Assad, Albert, Clark, Jason, O’Neill, Peter, Hoffman, Ronald, Verstovsek, Srdan

“…Background: Janus kinases (JAKs), including JAK1 and JAK2, mediate the signaling of cytokines and growth factors implicated in the pathogenesis of…”
Get full text

Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results by Verstovsek, Srdan, Mesa, Ruben A., Foltz, Lynda M., Gupta, Vikas, Mascarenhas, John, Ritchie, Ellen K., Hoffman, Ronald, Silver, Richard T., Hong, Wan-Jen, Kremyanskaya, Marina, Trehu, Elizabeth G., Kantarjian, Hagop M., Gotlib, Jason R.

“…Abstract only…”
Get full text

Improved Survival with Iron Chelation Therapy for Lower IPSS Risk MDS Appears to Have a Stronger Association in Patients with a Non-RARS Diagnosis by Leitch, Heather A, Chan, Christopher, Leger, Chantal S, Foltz, Lynda M, Ramadan, Khaled M, Vickars, Linda M

“…Abstract 1732 Several retrospective analyses suggest that transfusional iron overload portends inferior survival in lower risk MDS and that iron chelation…”
Get full text

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update by Martino, Bruno, le Coutre, Philipp, Griesshammer, Martin, Illmer, Thomas, Schlag, Rudolf, Waller, Cornelius F., Liberati, Anna Marina, Schafhausen, Philippe, Tavares, Renato S, Vannucchi, Alessandro M., Giraldo, Pilar, Foltz, Lynda M, Raanani, Pia, Gupta, Vikas, Tannir, Bayane, Ronco, Julian Perez, Ghosh, Jaggannath, Al-Ali, Haifa Kathrin

“…BACKGROUND Ruxolitinib is a potent JAK1/JAK2 inhibitor that has demonstrated reductions in splenomegaly and disease-related symptoms, as well as improved…”
Get full text

Diagnosis and Treatment of Essential Thrombocythemia: Assessment of Current Clinical Practice by Lee, Vivian H Y, Peterson, Erica, Zypchen, Leslie, Foltz, Lynda M

“…Abstract 1903 Poster Board I-926 The discovery of the JAK2 V617F gene mutation has significantly altered the clinical diagnostic approach to the…”
Get full text